M
Margaret A. Shipp
Researcher at Harvard University
Publications - 264
Citations - 42880
Margaret A. Shipp is an academic researcher from Harvard University. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Lymphoma. The author has an hindex of 87, co-authored 250 publications receiving 38048 citations. Previous affiliations of Margaret A. Shipp include University of Texas Medical Branch & Brigham and Women's Hospital.
Papers
More filters
Journal Article
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more
TL;DR: The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Journal ArticleDOI
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Bruce D. Cheson,Sandra J. Horning,B Coiffier,Margaret A. Shipp,Richard I. Fisher,J Connors,T A Lister,Julie M. Vose,Antonio J. Grillo-Lopez,A Hagenbeek,F Cabanillas,D Klippensten,W Hiddemann,R A Castellino,Nancy L. Harris,James O. Armitage,W. D. Carter,Richard T. Hoppe,George P. Canellos +18 more
TL;DR: Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL), and two meetings were convened among United States and international lymphoma experts to develop a uniform set of criteria for assessing response in clinical trials.
Journal ArticleDOI
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell,Alexander M. Lesokhin,Alexander M. Lesokhin,Ivan Borrello,Ahmad Halwani,Emma C. Scott,Martin Gutierrez,Stephen J. Schuster,Michael Millenson,Deepika Cattry,Gordon J. Freeman,Scott J. Rodig,Bjoern Chapuy,Azra H. Ligon,Lili Zhu,Joseph F. Grosso,Su Y oung Kim,John M. Timmerman,Margaret A. Shipp,Philippe Armand +19 more
TL;DR: Nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin's lymphoma.
Journal ArticleDOI
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
Margaret A. Shipp,Kenneth N. Ross,Pablo Tamayo,Andrew P. Weng,Jeffery L. Kutok,Ricardo C.T. Aguiar,Michelle Gaasenbeek,Michael Angelo,Michael R. Reich,Geraldine S. Pinkus,Tane S. Ray,Margaret A. Koval,Andrew Norton,T. Andrew Lister,Jill P. Mesirov,Donna Neuberg,Eric S. Lander,Jon C. Aster,Todd R. Golub +18 more
TL;DR: Genes implicated in DLBCL outcome included some that regulate responses to B-cell–receptor signaling, critical serine/threonine phosphorylation pathways and apoptosis, and identify rational targets for intervention.
Journal ArticleDOI
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy,Chip Stewart,Andrew Dunford,Jaegil Kim,Atanas Kamburov,Robert A. Redd,Michael S. Lawrence,Michael S. Lawrence,Margaretha G.M. Roemer,Amy Li,Marita Ziepert,Annette M. Staiger,Annette M. Staiger,Jeremiah Wala,Matthew D. Ducar,Ignaty Leshchiner,Ester Rheinbay,Amaro Taylor-Weiner,Caroline A. Coughlin,Julian M. Hess,Chandra Sekhar Pedamallu,Dimitri Livitz,Daniel Rosebrock,Mara Rosenberg,Adam Tracy,Heike Horn,Paul Van Hummelen,Andrew L. Feldman,Brian K. Link,Anne J. Novak,James R. Cerhan,Thomas M. Habermann,Reiner Siebert,Andreas Rosenwald,Aaron R. Thorner,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Todd R. Golub,Rameen Beroukhim,Rameen Beroukhim,Gerald Wulf,German Ott,Scott J. Rodig,Scott J. Rodig,Stefano Monti,Donna Neuberg,Markus Loeffler,Michael Pfreundschuh,Lorenz Trümper,Gad Getz,Gad Getz,Margaret A. Shipp +52 more
TL;DR: A comprehensive genetic analysis of 304 primary DLBCLs identified low-frequency alterations, captured recurrent mutations, somatic copy number alterations, and structural variants, and defined coordinate signatures in patients with available outcome data to provide a roadmap for an actionableDLBCL classification.